Meta-Analysis to Evaluate the Role of Interferon in Follicular Lymphoma

Rohatiner, A. Z. S.; Gregory, Walter M.; Peterson, Bruce A.; Ec, Borden; Solal‐Céligny, Philippe; Hagenbeek, Anton; Fisher, R I; Unterhalt, Michael; Arranz, Reyes; Chisesi, Teodoro; Avilés, Agustín; Lister, T. A.

doi:10.1200/jco.2005.06.146

Cited by 161 publications

(72 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…9 In line with other studies, 14,15 previous results from our co-operative group (GELF86 trial) demonstrated improved disease control associated with the addition of interferon to low-dose anthracycline combination chemotherapy regimen. This combination therapy was thus considered as the control arm of treatment for the present FL2000 trial.…”

Section: Treatmentssupporting

confidence: 76%

Long-term follow up of the FL2000 study comparing CHVP-interferon to CHVP-interferon plus rituximab in follicular lymphoma

Bachy¹,

Houot²,

Morschhauser³

et al. 2013

Haematologica

View full text Add to dashboard Cite

Section: Treatmentssupporting

confidence: 76%

Long-term follow up of the FL2000 study comparing CHVP-interferon to CHVP-interferon plus rituximab in follicular lymphoma

Bachy¹,

Houot²,

Morschhauser³

et al. 2013

Haematologica

View full text Add to dashboard Cite

“…Several groups have studied cytokines, such as IFN-a, IL-2, IL-12, and IL-21, as interventional targets in FL with mixed results. [55][56][57][58] Clearly, the role of cytokines in lymphoma biology is complex. The intertwined circuits of cytokines and different helper and effector cells secreting some of the elevated cytokines may represent an immune system response against the tumor and vice versa.…”

Section: Discussionmentioning

confidence: 99%

Elevated serum levels of IL-2R, IL-1RA, and CXCL9 are associated with a poor prognosis in follicular lymphoma

Mir¹,

Maurer²,

Ziesmer³

et al. 2015

Blood

View full text Add to dashboard Cite

• Elevated IL-2R, IL-1RA, and CXCL9 are associated with shorter event-free survival in newly diagnosed FL, treated with chemoimmunotherapy.• Increased serum IL-12 and IL-1RA is associated with shorter event-free survival in patients who were observed or treated with rituximab alone.Serum cytokines and chemokines may reflect tumor biology and host response in follicular lymphoma (FL). To determine whether the addition of these biological factors may further refine prognostication, 30 cytokines and chemokines were measured in pretreatment serum specimens from newly diagnosed FL patients (n 5 209) and from 400 matched controls. Cytokine levels were correlated with clinical outcome in patients who were observed or received single agent rituximab, or those who received chemotherapy.Correlations with outcome in chemotherapy treated patients were further examined in a separate cohort of 183 South West Oncology Group (SWOG) patients and all patients were then included in a meta-analysis. Six cytokines were associated with outcome in the Molecular Epidemiology Resource (MER) after adjusting for the FL international prognostic index. In patients who were observed or treated with rituximab alone, increased serum IL-12 and interleukin 1 receptor antagonist (IL-1RA) (P 5 .005 and .02) were associated with a shorter event-free survival. In patients receiving chemotherapy, hepatocyte growth factor, IL-8, IL-1RA, and CXCL9 (P 5 .015, .048, .004, and .0005) predicted a shorter EFS. When the MER chemotherapy treated patients and SWOG patients were combined in a meta-analysis, IL-2R, IL-1RA, and CXCL9 (P 5 .013, .042, and .0012) were associated with a poor EFS. (Blood. 2015;125(6):992-998) Introduction Follicular lymphoma (FL) is the second most common non-Hodgkin lymphoma in the United States.1 While classified as an indolent B-cell lymphoma, the clinical course exhibits a spectrum based on the FL international prognostic index (FLIPI) score with a remarkable tendency for patients to relapse.2 The overall survival rate of patients with FL was previous reported as 75% at 5 years, and ranged from 71% at 10 years for patients with a FLIPI score between 0 to 1, and 36% for those with a FLIPI score of .3. Currently, the median survival of all newly diagnosed patients is approximately 9 years. 3Although the overall survival appears to have improved with advances in chemoimmunotherapy, the median event free survival (EFS) remains around 2 years for patients with advanced disease. 4 As a prognostic score, the FLIPI has several limitations. It focuses on clinical factors and does not take into account biological factors such as the tumor microenvironment and the host response. Indeed, some studies have found better prognostication of the very high-risk group with the international prognostic index (IPI) rather than with the FLIPI. 5,6 The FLIPI may potentially be further improved, particularly in the high-risk categories, if biological data are added. Gene expression profiling studies on pretreatment specimens from patients with FL hav...

show abstract

“…Use of rIFN-a2b has been shown to reduce the recurrence rate but not change overall survival when used in combination with single-agent chemotherapy for low-grade lymphoma [14,15]. Maintenance rIFN-a2b after induction treatment with single-agent cyclophosphamide likewise showed no improvement in overall survival [16].…”

Section: Discussionmentioning

confidence: 99%

Remission of natural-killer cell lymphoma of the liver with anti-hepatitis C therapy

Armor

Fazili

Toubia³

et al. 2005

Am. J. Hematol.

View full text Add to dashboard Cite

Non-Hodgkin lymphomas (NHL) consist of a diverse group of lymphoproliferative neoplasms with unique patterns of biology, behavior, and differing responses to therapy. A rare subtype of malignancy arising from cells of putative natural killer (NK) origin is being recognized as a distinct clinicopathological entity. Viruses including hepatitis C have been reported in association with various types of NHL but not the NK-cell subtype. We hereby report a unique case of a patient with hepatitis C who developed hepatic NK-cell lymphoma and chronic NK-cell leukemia. Interestingly, we observed clinical and radiologic remission of the neoplasm following treatment with anti-hepatitis C therapy. Am.

show abstract

Meta-Analysis to Evaluate the Role of Interferon in Follicular Lymphoma

Abstract: When given in the context of relatively intensive initial chemotherapy, and at a dose >/= 5 million units (>/= 36 x 10(6) units per month), IFN-alpha2 prolongs survival and remission duration in patients with follicular lymphoma.

Cited by 161 publications

References 37 publications

Long-term follow up of the FL2000 study comparing CHVP-interferon to CHVP-interferon plus rituximab in follicular lymphoma

Long-term follow up of the FL2000 study comparing CHVP-interferon to CHVP-interferon plus rituximab in follicular lymphoma

Elevated serum levels of IL-2R, IL-1RA, and CXCL9 are associated with a poor prognosis in follicular lymphoma

Remission of natural-killer cell lymphoma of the liver with anti-hepatitis C therapy

Contact Info

Product

Resources

About